Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04663347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04663347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 3, 2020
Completion date
September 30, 2027
Enrollment
543 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, follicular lymphoma